Oral GLP-1s Offer a Safer, Regulated Alternative to the Booming Unregulated Peptide Market

The conversation around GLP-1 receptor agonists has become difficult to navigate. On one side are the FDA-approved medications — injectable semaglutide and tirzepatide, and a growing set of oral options including Rybelsus, the Wegovy pill, and Lilly's newly approved Foundayo — that have transformed care for type 2 diabetes and obesity. On the other is a fast-growing gray market of compounded peptides, research-chemical-grade injectables, and unverified oral formulations being marketed through wellness clinics, telehealth shortcuts, and online pharmacies that operate well outside the FDA's regulatory perimeter. For patients, clinicians, and public health officials, the gap between these two markets has real consequences.

What "unregulated peptides" actually means

The term peptide is being used loosely in consumer-facing marketing. In legitimate clinical use, peptides like semaglutide are manufactured under strict pharmaceutical-grade conditions, dosed precisely, and dispensed under prescriber supervision. In the gray market, "peptides" often refers to compounded or research-grade injectables sourced from facilities with limited oversight, dosed inconsistently, and frequently sold for off-label use without appropriate clinical workup. The active ingredients may or may not match the label. Sterility, potency, and purity vary from batch to batch. And patients using these products often do so without the metabolic monitoring, contraindication screening, or adverse event reporting that accompanies a prescribed regimen.

Why this matters now

Demand for GLP-1 therapies has outstripped pharmaceutical supply at multiple points over the past several years, and the supply gap has been a powerful driver of the gray market. FDA declared the national shortages of tirzepatide and semaglutide resolved in late 2024 and early 2025, yet the gray market has persisted. When patients cannot access an approved product through their pharmacy, some turn to compounded versions, online vendors, or wellness clinics that fill the gap with products of uncertain provenance. Adverse events tied to unapproved GLP-1 products are mounting: FDA has received hundreds of adverse event reports linked to compounded semaglutide and tirzepatide, some requiring hospitalization and many tied to dosing errors, and has warned that products falsely labeled "for research purposes" or "not for human consumption" are of unknown quality and may be harmful. These are the harms that make headlines. The slower, harder-to-quantify harm is the erosion of patient trust in a therapeutic class that, when used properly, has remarkable evidence behind it.

The case for oral GLP-1s

Oral GLP-1s now offer a pathway that addresses many of the practical concerns patients cite when they consider gray-market alternatives. Rybelsus (oral semaglutide), approved in 2019 for type 2 diabetes, has been joined by the Wegovy pill, approved in December 2025 for weight management, and Foundayo (orforglipron), approved in April 2026 for chronic weight management. No injection is required, which removes a meaningful adoption barrier for patients who are needle-averse or who travel frequently. These medications are manufactured under FDA oversight, dosed consistently, and dispensed through legitimate pharmacy channels. Oral semaglutide has been studied extensively in randomized trials, and in 2025 FDA added a cardiovascular risk-reduction indication to Rybelsus for high-risk adults with type 2 diabetes. And because they are dispensed by prescription, patients receive the appropriate clinical workup, ongoing monitoring, and integration with the rest of their care.

For payers and health systems, oral GLP-1s also simplify a number of operational challenges. Pill-based therapy fits easily into existing pharmacy benefit infrastructure. Adherence patterns are well understood. Drug-drug interactions are well documented. The clinical evidence base is robust and continues to expand. None of this is true of compounded or research-grade alternatives.

What clinicians and public health agencies can do

The response to the gray-market peptide boom is not prohibition; demand will not disappear, and patients pursuing these products are usually doing so because they perceive — sometimes accurately — that approved channels are not working for them. The response is to make the legitimate path easier. That means clinician education about oral GLP-1 options, reimbursement policy that does not steer patients toward off-label compounded alternatives, and patient-facing communication that explains the meaningful differences between FDA-approved medications and the gray-market products being marketed to look similar.

It also means stronger surveillance. Public health agencies should be tracking adverse events tied to gray-market peptides as a distinct category, partnering with poison control centers, and working with state medical and pharmacy boards to address clinics and vendors that operate outside legitimate scope-of-practice norms.

The broader frame

GLP-1s are one of the most consequential pharmaceutical innovations of the last decade. The therapeutic class deserves careful stewardship, including a public health infrastructure that helps patients access the approved products that work, recognize the gray-market products that may not, and trust that their clinicians and health systems are working in their interest. Oral GLP-1s like Rybelsus, the Wegovy pill, and Foundayo are an important part of that picture — a regulated, evidence-backed alternative to a gray market that is growing faster than its safety profile justifies.

AR+D's healthcare practice partners with public health agencies, health systems, and pharmaceutical commercialization teams on exactly these questions — designing patient education, clinician training, and health communication strategies that meet patients where they are without compromising on the evidence that should guide their care.